250 related articles for article (PubMed ID: 28789947)
1. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
2. Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
Kearns JT; Faino AV; Schenk JM; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner A; Zheng Y; Lin DW
J Urol; 2019 Jan; 201(1):106-111. PubMed ID: 30076904
[TBL] [Abstract][Full Text] [Related]
3. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
Bonde Miranda T; Garmo H; Stattin P; Robinson D
J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.
Fradet V; Toren P; Nguile-Makao M; Lodde M; Lévesque J; Léger C; Caron A; Bergeron A; Ben-Zvi T; Lacombe L; Pouliot F; Tiguert R; Dujardin T; Fradet Y
BJU Int; 2018 Mar; 121(3):399-404. PubMed ID: 28972698
[TBL] [Abstract][Full Text] [Related]
5. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
6. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
10. Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.
Taussky D; Piotte J; Zorn KC; Zanaty M; Krishnan V; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Delouya G
Strahlenther Onkol; 2018 Jan; 194(1):17-22. PubMed ID: 28695317
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z; Gleave ME; Kunju P; Lance RS; McKenney JK; Meng MV; Nicolas MM; Sanda MG; Simko J; So A; Tretiakova MS; Troyer DA; True LD; Vakar-Lopez F; Virgin J; Wagner AA; Wei JT; Zheng Y; Nelson PS; Lin DW;
J Urol; 2016 Feb; 195(2):313-20. PubMed ID: 26327354
[TBL] [Abstract][Full Text] [Related]
12. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
14. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
[TBL] [Abstract][Full Text] [Related]
15. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
16. An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.
Komisarenko M; Wong LM; Richard PO; Timilshina N; Toi A; Evans A; Zlotta A; Kulkarni G; Hamilton R; Fleshner N; Finelli A
J Urol; 2016 Feb; 195(2):307-12. PubMed ID: 26417646
[TBL] [Abstract][Full Text] [Related]
17. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
18. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
19. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Murtola TJ; Kujala PM; Tammela TL
Prostate; 2013 Jun; 73(9):923-31. PubMed ID: 23334943
[TBL] [Abstract][Full Text] [Related]
20. Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.
Hong SK; Oh JJ; Lee S; Lee HM; Byun SS; Choe G; Lee SE
Prostate; 2012 Aug; 72(11):1187-92. PubMed ID: 22161951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
